[{"address1": "301 Binney Street", "address2": "Suite 402", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 401 9975", "website": "https://www.synlogictx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Ms. Mary Beth Dooley", "age": 42, "title": "Principal Executive Officer & Principal Financial Officer", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ajay  Munshi", "title": "Vice President of Corporate Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neal  Sondheimer M.D., Ph.D.", "title": "VP & Head of Clinical", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jose-Carlos  Gutierrez-Ramos Ph.D.", "age": 62, "title": "Advisor", "yearBorn": 1962, "fiscalYear": 2018, "totalPay": 597133, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1546214400, "maxAge": 86400, "priceHint": 4, "previousClose": 1.4, "open": 1.36, "dayLow": 1.36, "dayHigh": 1.4, "regularMarketPreviousClose": 1.4, "regularMarketOpen": 1.36, "regularMarketDayLow": 1.36, "regularMarketDayHigh": 1.4, "beta": 0.809, "forwardPE": -2.9787233, "volume": 11084, "regularMarketVolume": 11084, "averageVolume": 39228, "averageVolume10days": 19740, "averageDailyVolume10Day": 19740, "marketCap": 16374540, "fiftyTwoWeekLow": 1.22, "fiftyTwoWeekHigh": 2.16, "priceToSalesTrailing12Months": 5.8964853, "fiftyDayAverage": 1.41412, "twoHundredDayAverage": 1.50385, "currency": "USD", "enterpriseValue": -3014447, "floatShares": 2235243, "sharesOutstanding": 11696100, "sharesShort": 53196, "sharesShortPriorMonth": 61044, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0045, "heldPercentInsiders": 0.14191, "heldPercentInstitutions": 0.64609003, "shortRatio": 2.47, "shortPercentOfFloat": 0.0135, "impliedSharesOutstanding": 11696100, "bookValue": 1.121, "priceToBook": 1.2488848, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -37179000, "trailingEps": -1.5, "forwardEps": -0.47, "lastSplitFactor": "1:7", "lastSplitDate": 1503878400, "enterpriseToRevenue": -1.086, "enterpriseToEbitda": 0.124, "52WeekChange": -0.23913044, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SYBX", "underlyingSymbol": "SYBX", "shortName": "Synlogic, Inc.", "longName": "Synlogic, Inc.", "firstTradeDateEpochUtc": 1443619800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "30bbb3c7-ab0a-33b2-91a8-e57d2c890111", "messageBoardId": "finmb_268899196", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.4, "targetHighPrice": 1.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.0, "targetMedianPrice": 1.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 19389000, "totalCashPerShare": 1.658, "ebitda": -24275000, "quickRatio": 2.536, "currentRatio": 2.708, "totalRevenue": 2777000, "revenuePerShare": 0.229, "returnOnAssets": -0.35952, "returnOnEquity": -1.3157899, "grossProfits": 2777000, "freeCashflow": -5263625, "operatingCashflow": -36618000, "grossMargins": 1.0, "operatingMargins": -9.011519, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]